CRISPR treatment for rare genetic eye disorder gains FDA study approval


Days after a Chinese researcher incensed the world of science with claims of editing the genomes of twin girls, an American company is plotting a CRISPR trial of its own. But in place of the secrecy and stagecraft that marked the Chinese experiment, Editas Medicine went the old-fashioned way: waiting for approval from the Food and Drug Administration.

The company, headquartered in Cambridge, Mass., got the FDA’s blessing to test a CRISPR-based therapy on patients with a rare genetic disorder that leads to blindness. Editas, which is partnered with Botox maker Allergan, said it plans to enroll between 10 and 20 patients in a study to test the treatment’s safety and efficacy.

The timing is entirely coincidental: Editas asked the FDA’s permission back in October, long before He Jiankui went public with his controversial experiment. And the two ideas, while both employing CRISPR, are vastly different: While He edited embryos, making genomic changes that would be passed down to future children, Editas is targeting cells in the eye that play no role in reproduction.

Related article:  Promoting CRISPR crops at the expense of GMOs is short-sighted when we need both


BIO, the industry’s lobbying group, issued a statement [November 28] calling the Chinese experiment “deeply troubling” and underlining the fact that none of its member companies are working on CRISPR projects that would result in heritable changes to anyone’s DNA.

Read full, original post: FDA signs off on Editas CRISPR study on patients with a rare genetic disorder

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...

Gilles-Éric Séralini: Activist professor and face of anti-GMO industry

The French biologist and his research team--funded by the Rodale ...
vandana shiva

Vandana Shiva: ‘Rock Star’ of GMO protest movement has anti-science history

In a 2012 interview, Bill Moyers referred to Vandana Shiva as ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend